Filtered By:
Source: Nanomedicine: Nanotechnology, Biology and Medicine
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 65 results found since Jan 2013.
Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC
Publication date: Available online 12 May 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Dhananjay Suresh, Ajit Zambre, Soumavo Mukherjee, Shreya Ghoshdastidar, Yuexu Jiang, Trupti Joshi, Anandhi Upendran, Raghuraman KannanAbstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer mortality with the 5-year survival rate remains a dismal 16% for the past 40 years. Drug resistance is a major obstacle to achieving long-term patient survival. Identifying and validating molecular biomarkers responsible for resistance and thereby adopting multi-directional therapy is necessary to imp...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 12, 2019 Category: Nanotechnology Source Type: research
Single-Step Microfluidic Synthesis of Transferrin-Conjugated Lipid Nanoparticles for siRNA Delivery
In this study, a single-step process based on microfluidic focusing (MF) was employed to synthesize transferrin-conjugated lipid nanoparticles (Tf-LNPs) and the method was compared with a multi-steps bulk mixing (BM) method. The results indicate that this single-step MF process enables rapid and efficient synthesis of Tf-LNPs, which were named Tf-LNPs-MF. Tf-LNPs-MF was shown to have a smaller size and more uniform structures compared to LNPs produced by multi-steps BM method (Tf-LNPs-BM). Furthermore, efficient cellular uptake of Tf-LNPs-MF in vitro as well as greater tumor inhibition in vivo proved that Tf-LNPs-MF had hi...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - October 9, 2016 Category: Nanotechnology Source Type: research
Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models
Publication date: Available online 25 November 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Cai M. Roberts, Sophia Allaf Shahin, Wei Wen, James B. Finlay, Juyao Dong, Ruining Wang, Thanh H. Dellinger, Jeffrey I. Zink, Fuyuhiko Tamanoi, Carlotta A. Glackin Epithelial ovarian cancer (EOC) is the most deadly gynecologic malignancy on account of its late stage at diagnosis and frequency of drug resistant recurrences. Novel therapies to overcome these barriers are urgently needed. TWIST is a developmental transcription factor reactivated in cancers and linked to angiogenesis, metastasis, cancer ste...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 24, 2016 Category: Nanotechnology Source Type: research
Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer
Publication date: Available online 14 April 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Sophia A. Shahin, Ruining Wang, Shirleen I. Simargi, Altagracia Contreras, Liliana Parra, Louise Qu, Wei Wen, Thanh Dellinger, Juli Unternaehrer, Fuyuhiko Tamanoi, Jeffrey I. Zink, Carlotta A. Glackin TWIST protein is critical to development and is activated in many cancers. TWIST regulates epithelial-mesenchymal transition, and is linked to angiogenesis, metastasis, cancer stem cell phenotype, and drug resistance. The majority of epithelial ovarian cancer (EOC) patients with metastatic disease respond wel...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - April 15, 2018 Category: Nanotechnology Source Type: research
Site-specific intestinal DMT1 silencing to mitigate iron absorption using pH-sensitive multi-compartmental nanoparticulate oral delivery system
We report a novel pH-sensitive multi-compartmental nanoparticulate (MCP) oral delivery system that encapsulates siRNA for silencing the divalent metal transporter 1 (DMT1) gene, a primary iron transporter highly expressed in the intestine. The gelatin nanoparticles-coated with Eudragit® L100–55 are able to protect siRNA from intracellular degradation and allow for sustained release of siRNA in the cytosol. When orally-administered, Eudragit® L100–55 based MCPs containing DMT1 siRNA/gelatin NPs specifically and significantly decreased the expression of DMT1 mRNA in the duodenum, which consequently decreased intestinal...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - October 16, 2019 Category: Nanotechnology Source Type: research
Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment
Publication date: Available online 16 November 2017 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Narsireddy Amreddy, Anish Babu, Janani Panneerselvam, Akhil Srivastava, Ranganayaki Muralidharan, Allshine Chen, Yan D. Zhao, Anupama Munshi, Rajagopal Ramesh Co-administration of functionally distinct anti-cancer agents has emerged as an efficient strategy in lung cancer treatment. However, a specially designed drug delivery system is required to co-encapsulate functionally different agents, such as a combination of siRNA and chemotherapy, for targeted delivery. We developed a folic acid (FA) -conjugat...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 28, 2017 Category: Nanotechnology Source Type: research
Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system
This study demonstrates superior therapeutic properties of siRNA when combined with a dendrimer-based targeted nano-delivery system. Similar approaches may eventually gain clinical utility following additional studies determining safety and efficacy. Graphical abstract
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 10, 2014 Category: Nanotechnology Source Type: research
Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells
Publication date: Available online 18 February 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Jing Chen, Yushun Dou, Yue Tang, Xinru ZhangAbstractWe developed a STAT3 silencing siRNA to both tumor cells and M2 macrophages. The dual-targeting system prepared by electronic self-assembly was composed of folic acid-conjugated carboxymethyl chitosan for targeting and cationic chitosan derivatives for siRNA package. The effects of siRNA delivery was investigated in M2 macropahges and Lewis lung cancer cells(LLC). Due to the enhanced delivery efficiency, the dual-targeting delivery system exhibited a hig...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - February 19, 2020 Category: Nanotechnology Source Type: research
Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem
Publication date: Available online 21 April 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Yujuan Zhang, Xuelin Zhan, Shanshan Peng, Ying Cai, Yu Shrike Zhang, Yanling Liu, Zhigang Wang, Yanrong Yu, Yifan Wang, Qiaofa Shi, Xiaoping Zeng, Keng Yuan, Nanjin Zhou, Rakesh Joshi, Meng Zhang, Zhuxu Zhang, Weiping Min Melanoma is significantly associated with mutant BRAF gene, a suitable target for siRNA-based anti-melanoma therapy. However, a tumor-specific delivery system is a major hurdle for clinical applications. Here, we developed a novel nano-carrier, FA-GNR-siBRAF for safe topical application, ...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 13, 2018 Category: Nanotechnology Source Type: research
Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis
This report describes the development of polyplexes based on CXCR4-inhibiting poly(ethylenimine) derivative (PEI-C) for pulmonary delivery of siRNA to silence plasminogen activator inhibitor-1 (siPAI-1) as a new combination treatment of pulmonary fibrosis (PF). Safety and delivery efficacy of the PEI-C/siPAI-1 polyplexes was investigated in vitro in primary lung fibroblasts isolated from mice with bleomycin-induced PF. Biodistribution analysis following intratracheal administration of fluorescently labeled polyplexes showed prolonged retention in the lungs. Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 5, 2018 Category: Nanotechnology Source Type: research
Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem
Publication date: July 2018Source: Nanomedicine: Nanotechnology, Biology and Medicine, Volume 14, Issue 5Author(s): Yujuan Zhang, Xuelin Zhan, Shanshan Peng, Ying Cai, Yu Shrike Zhang, Yanling Liu, Zhigang Wang, Yanrong Yu, Yifan Wang, Qiaofa Shi, Xiaoping Zeng, Keng Yuan, Nanjin Zhou, Rakesh Joshi, Meng Zhang, Zhuxu Zhang, Weiping MinAbstractMelanoma is significantly associated with mutant BRAF gene, a suitable target for siRNA-based anti-melanoma therapy. However, a tumor-specific delivery system is a major hurdle for clinical applications. Here, we developed a novel nano-carrier, FA-GNR-siBRAF for safe topical applicati...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 5, 2018 Category: Nanotechnology Source Type: research
Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis
This report describes the development of polyplexes based on CXCR4-inhibiting poly(ethylenimine) derivative (PEI-C) for pulmonary delivery of siRNA to silence plasminogen activator inhibitor-1 (siPAI-1) as a new combination treatment of pulmonary fibrosis (PF). Safety and delivery efficacy of the PEI-C/siPAI-1 polyplexes was investigated in vitro in primary lung fibroblasts isolated from mice with bleomycin-induced PF. Biodistribution analysis following intratracheal administration of fluorescently labeled polyplexes showed prolonged retention in the lungs. Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 10, 2018 Category: Nanotechnology Source Type: research
Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient Down-regulation of variant PTPN22 gene in T lymphocytes
Publication date: Available online 12 November 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Marsha Pellegrino, Francesca Ceccacci, Stefania Petrini, Marco Cappa, Giovanna Mancini, Alessandra FierabracciAbstractIn autoimmune diseases as Type 1 diabetes, the actual treatment that provides the missing hormones is not able, however, to interrupt the underlining immunological mechanism. Importantly, novel immunotherapies are exploited to protect and rescue the remaining hormone producing cells. Among probable targets of immunotherapy, the C1858T mutation in the PTPN22 gene, which encodes for the lymp...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 12, 2018 Category: Nanotechnology Source Type: research
A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer
Publication date: Available online 6 October 2014 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Maria de la Fuente , Marie-Christine Jones , Manuel J. Santander-Ortega , Anja Mirenska , Preethi Marimuthu , Ijeoma Uchegbu , Andreas Schätzlein Gemcitabine is currently the standard therapy for pancreatic cancer. However, growing concerns over gemcitabine resistance mean that new combinatory therapies are required to prevent loss of efficacy with prolonged treatment. Here, we suggest that this could be achieved through co-administration of RNA interference agents targeting the ubiquitin ligase ITCH. S...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 4, 2014 Category: Nanotechnology Source Type: research
Atg5 deficit exaggerates the lysosome formation and cathepsin B activation in mice brain after lipid nanoparticles injection
Publication date: November 2014 Source:Nanomedicine: Nanotechnology, Biology and Medicine, Volume 10, Issue 8 Author(s): Nan-nan Lu , Jun Liu , Yun Tian , Mei-hua Liao , Huan Wang , Ying-mei Lu , Rong-rong Tao , Ling-juan Hong , Shuang-shuang Liu , Kohji Fukunaga , Yong-zhong Du , Feng Han The present study was designed to investigate the role of autophagy-lysosome signaling in the brain after application of nanoparticles. Here, lipid nanoparticles (LNs) induced elevations of Atg5, P62, LC3 and cathepsin B in mice brain. The transmission electron microscopy revealed a dramatic elevation of lysosome vacuoles colocalized w...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 10, 2014 Category: Nanotechnology Source Type: research
